Quick Links

Schistosomiasis Vaccine Study

Schistosomiasis Vaccine Study

We are currently recruiting participants for a clinical trial of an investigational vaccine against schistosomiasis. The trial is sponsored by the U.S. National Institutes of Health (NIH).

Schistosomiasis is a disease caused by a worm-like parasite. Globally more than 200 million people are infected worldwide, most commonly in sub-Saharan Africa, leading to hundreds of thousands of deaths each year. There is currently no approved vaccine for schistosomiasis. This investigational vaccine, called Sm-p80 + GLA-SE (SchistoShield®), includes a synthetic protein made in a laboratory and the GLA-SE adjuvant, which is a substance that increases the body’s response to vaccines. It does not contain any parts of the schistosomiasis parasite and cannot cause infection. The goal of this study is to evaluate the safety of and immune responses to the Sm-p08 + GLA-SE vaccine.

The study involves three injections of the investigational vaccine, with up to 13 scheduled study clinic visits and 2 telephone visits over a period of up to 19 months. The vaccination visits will take up to three hours, and the other clinic visits will take about 30 minutes. Participants will receive a $75 payment for each clinic visit. Free parking or bus tickets are provided.

Participant Eligibility

• Healthy adults age 18 to 55 years
• Able to attend all study visits at the Kaiser Permanente Washington Health Research Institute clinic in downtown Seattle
• Not pregnant, and if able to become pregnant, willing to use an acceptable form of birth control
• No medical conditions that affect the immune system and not taking medications that affect the immune system
• No previous potential exposure to schistosomiasis (swimming or wading in freshwater sources, like lakes or rivers, in Africa or other parts of the world where schistosomiasis occurs)
• There are other conditions that may make you ineligible for this study

Contact

Maya Dunstan, RN
(206) 287-2061

Additional Study Details

Full Study Title
A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Vaccine in Healthy Adults

Study ID: Pro00059240
Start Date: 11/24/2021
End Date: 12/31/2022

Investigator(s)
Lisa A. Jackson, MD, MPH

Accepts Healthy Volunteers?
Yes

Study Site(s)

Kaiser Permanente Washington Health Research Institute

1730 Minor Ave 1370
Seattle, Washington 98101



Interested?

Use the link below to send a message to the study coordinator, or call the number above to speak directly with a study representative.

I am interested in this research study.

SITE PARTNERS
uw-footer